Skip to main content
. 2023 Feb 6;80(3):287–297. doi: 10.1001/jamaneurol.2022.5250

Figure 3. Kaplan-Meier Curves Using Combined Biomarker Data to Predict Time to Confirmed Disease Worsening (CDW).

Figure 3.

Optimized cutoffs of serum glial fibrillary acidic protein (sGFAP) and serum neurofilament light chain (sNfL) z scores from receiver operating characteristic curve analysis, based on the Youden index, were used to dichotomize patient groups. High sGFAP/high sNfL levels were associated with a 4-fold (hazard ratio [HR], 4.09; 95% CI, 2.04-8.18; P < .001) increased risk of CDW compared with low sGFAP/low sNfL levels. The combination of high sGFAP/low sNfL levels showed a slightly reduced risk (HR, 2.32; 95% CI, 0.99-5.42; P = .05). The combination of low sGFAP/high sNfL levels, however, did not show an increased risk on CDW (HR, 1.03; 95% CI, 0.30-3.53; P = .97).